Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Lance Leopold, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
101 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Austin Health-Austin Hospital
Heidelberg, Victoria, Australia
- St John of God Murdoch Medical Clinic
Murdoch, Western Australia, Australia
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Moncton Hospital - Horizon Health Network
Moncton, New Brunswick, Canada
- William Osler Health System
Brampton, Ontario, Canada
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
- Sault Area Hospital
Sault Ste. Marie, Ontario, Canada
- Rigshospitalet
Copenhagen, Denmark
- Regionshospitalet Herning
Herning, Denmark
- Odense Universitetshospital
Odense, Denmark
- Sa Tartu Ulikooli Kliinikum
Tartu, Estonia
- Galway University Hospital
Galway, Connacht, Ireland
- St Vincents University Hospital
Dublin, Ireland
- Soroka Medical Center
Beersheba, Israel
- Rambam Medical Center
Haifa, Israel
- Meir Medical Center
Kfar Saba, Israel
- Rabin Medical Center
Petah Tikva, Israel
- Chaim Sheba Medical Center
Ramat Gan, Israel
- Irccs A.O.U. San Martino - Ist
Genova, Italy
- Policlinico Universitario Agostino Gemelli
Roma, Italy
- National Hospital Organization Nagoya Medical Center
Nagoya, Aichi-ken, Japan
- National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
- Kurume University Hospital
Kurume, Fukuoka, Japan
- Kanazawa University Hospital
Kanazawa, Ishikawa-ken, Japan
- Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
- Sendai Kousei Hospital
Sendai, Miyagi, Japan
- Kansai Medical University Hospital
Hirakata, Osaka, Japan
- Kindai University Hospital
Sayama, Osaka, Japan
- Shizuoka Cancer Center
Nagaizumi-chō, Shizuoka, Japan
- Kyushu University Hospital
Fukuoka, Japan
- National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
- Niigata Cancer Center Hospital
Niigata, Japan
- Okayama University Hospital
Okayama, Japan
- National Cancer Center Hospital
Tokyo, Japan
- Nippon Medical School Hospital
Tokyo, Japan
- the Cancer Institute Hospital of Jfcr
Tokyo, Japan
- Wakayama Medical University Hospital
Wakayama, Japan
- Institut Kanser Negara - National Cancer Institute
Putrajaya, Kuala Lumpur, Malaysia
- Hospital Tengku Ampuan Afzan
Kuantan, Pahang, Malaysia
- Pantai Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Dec 2017
- Primary completion
- 10 Jan 2019
- Completion
- 9 Nov 2020
- Last update posted
- 22 Aug 2025
- Registered enrollment
- 154
- Registry id
- NCT03322540
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.